Our study showed that the application of the MLE containing the pseudoceramide PC-9S and SPHK1 activator DefensamideTM with topical corticosteroid significantly improved the skin barrier function, clinical symptoms, and quality of life of patients with AD across a wide age range. The gene discussed is SPHK1; the disease is Alzheimer disease.